



Achillion Pharmaceuticals  
Investor Relations Department  
300 George St.  
New Haven, CT 06511  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: ACHN**

Last Trade: 3.43

Trade Time: 4:00 PM ET  
Nov 17, 2017

Change: -0.13 ↓ (-3.652%)

Day Range 3.38 - 3.55

52-Week Range 2.95 - 5.66

Volume 1,995,620

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

### Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Nov 15, 2017

[Achillion Announces Pricing of Secondary Offering Of Common Stock](#)

Nov 14, 2017

[Achillion Announces Proposed Secondary Offering of Common Stock](#)

Nov 14, 2017

[Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G](#)

Nov 6, 2017

[Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria](#)

Nov 1, 2017

[Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs](#)

## Financial Disclosures [\[ View all \]](#)

[Third Quarter Financial Results](#)

Feb 23, 2017

[Annual Report \(10-K\)](#)

Apr 17, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)